Zieba A, Pawłowski L
Kliniki Psychiatrii Dorosłych AM w Krakowie.
Psychiatr Pol. 1993 May-Jun;27(3):317-24.
Considering the ever growing number of new discoveries and changes in ideas in the field of psychopharmacology, the authors present the actual state of knowledge about the mechanism of action of antidepressant drugs. Three periods characterize the research and the development of antidepressants. In the first period the presynaptic monoamine neuron was considered as the target structure both with respect to the search for the origin of depression and the mechanism of action of antidepressants. Two types of antidepressants, monoamine uptake inhibitors and monoamine oxidase inhibitors (IMAO) are representative of this period. In the second period, the research focused its interest primarily on monoaminergic receptors, anticipating that they were critically involved in the pathophysiology of depression. Such research sought to explain the antidepressant properties of iprindole and mianserine which are neither monoamine uptake inhibitors nor inhibitors of MAO. The onset of the third period is recent and it is characterized by the shift in research emphasis to intracellular transmission events. This period started with the discovery of the antidepressant properties of the phosphodiesterase inhibitor rolipram.
鉴于精神药理学领域新发现和观念变化的不断增加，作者介绍了关于抗抑郁药物作用机制的当前知识状况。抗抑郁药物的研究和开发可分为三个阶段。在第一阶段，无论是在寻找抑郁症的根源还是抗抑郁药物的作用机制方面，突触前单胺能神经元都被视为目标结构。两种类型的抗抑郁药物，单胺摄取抑制剂和单胺氧化酶抑制剂（MAOI）是这一时期的代表。在第二阶段，研究主要集中在单胺能受体上，预计它们在抑郁症的病理生理学中起关键作用。此类研究试图解释既不是单胺摄取抑制剂也不是MAO抑制剂的茚达品和米安色林的抗抑郁特性。第三阶段是最近才开始的，其特点是研究重点转向细胞内传递事件。这个阶段始于磷酸二酯酶抑制剂咯利普兰的抗抑郁特性的发现。
